Policy Title |
Policy Number |
Effective Date |
AbobotulinumtoxinA (Dysport) (PDF) |
CP.PHAR.230 |
June 1, 2024 |
Actemra (PDF) |
QCP.PHAR.001 |
Retire by January 1, 2025 |
ADAMTS13, recombinant-krhn (Adzynma) (PDF) |
CP.PHAR.635 |
August 1, 2024 |
Ado-Trastuzumab Emtansine (Kadcyla) (PDF) |
CP.PHAR.229 |
June 1, 2024 |
Aducanumab-avwa (Aduhelm) (PDF) |
CP.PHAR.468 |
June 1, 2024 |
Afamelanotide (Scenesse) (PDF) |
CP.PHAR.444 |
May 1, 2024 |
Afamitresgene Autoleucel (Tecelra) (PDF) |
CP.PHAR.678 |
January 1, 2025 |
Aflibercept (Eylea, Eylea HD) (PDF) |
CP.PHAR.184 |
November 1, 2024 |
Agalsidase Beta (Fabrazyme) (PDF) |
CP.PHAR.158 |
July 1, 2024 |
Alemtuzumab (Lemtrada) (PDF) |
CP.PHAR.243 |
June 1, 2024 |
Alglucosidase Alfa (Lumizyme) (PDF) |
CP.PHAR.160 |
July 1, 2024 |
Allogeneic Cultured Keratinocytes and Dermal Fibroblasts in Murine Collagen-dsat (StrataGraft) (PDF) |
CP.PHAR.562 |
May 1, 2024 |
Allogenic Processed Thymus Tissue-agdc (Rethymic) (PDF) |
CP.PHAR.563 |
May 1, 2024 |
Alpha1-Proteinase Inhibitors (Aralast NP, Glassia, Prolastin-C, Zemaira) (PDF) |
CP.PHAR.94 |
May 1, 2024 |
Amisulpride (Barhemsys) (PDF) |
CP.PMN.236 |
October 1, 2024 |
Amivantamab-vmjw (Rybrevant) (PDF) |
CP.PHAR.544 |
January 1, 2025 |
Amivantamab-vmjw (Rybrevant) (PDF) |
CP.PHAR.544 |
Retire by January 1, 2025 |
Anifrolumab-fnia (Saphnelo) (PDF) |
CP.PHAR.551 |
Retire by March 1, 2025 |
Anifrolumab-fnia (Saphnelo) (PDF) |
CP.PHAR.551 |
March 1, 2025 |
Anti-Inhibitor Coagulant Complex, Human (Feiba) (PDF) |
CP.PHAR.217 |
May 1, 2024 |
Antithrombin III (ATryn, Thrombate III) (PDF) |
CP.PHAR.564 |
May 1, 2024 |
Antithymocyte Globulin (Atgam, Thymoglobulin) (PDF) |
CP.PHAR.506 |
Retire by January 1, 2025 |
Antithymocyte Globulin (Atgam, Thymoglobulin) (PDF) |
CP.PHAR.506 |
January 1, 2025 |
Aripiprazole Long-Acting Injections (Abilify Maintena, Abilify Asimtufii, Aristada, Aristada Initio) (PDF) |
CP.PHAR.290 |
May 1, 2024 |
Asenapine (Saphris, Secuado) (PDF) |
CP.PMN.15 |
January 1, 2025 |
Asfotase Alfa (Strensiq) (PDF) |
CP.PHAR.328 |
January 1, 2025 |
Atezolizumab (Tecentriq) (PDF) |
CP.PHAR.235 |
May 1, 2024 |
Atidarsagene autotemcel (Lenmeldy) (PDF) |
CP.PHAR.602 |
September 1, 2024 |
Avacincaptad pegol (Izervay) (PDF) |
CP.PHAR.641 |
Retire by March 1, 2025 |
Avacincaptad pegol (Izervay) (PDF) |
CP.PHAR.641 |
March 1, 2025 |
Avalglucosidase Alfa-ngpt (Nexviazyme) (PDF) |
CP.PHAR.521 |
July 1, 2024 |
Avelumab (Bavencio) (PDF) |
CP.PHAR.333 |
May 1, 2024 |
Axatilimab-csfr (Niktimvo) (PDF) |
CP.PHAR.691 |
January 1, 2025 |
Axicabtagene Ciloleucel (Yescarta) (PDF) |
CP.PHAR.362 |
May 1, 2024 |
Azacitidine (Onureg, Vidaza) (PDF) |
CP.PHAR.387 |
Retire by March 1, 2025 |
Azacitidine (Onureg, Vidaza) (PDF) |
CP.PHAR.387 |
March 1, 2025 |
Baclofen (Fleqsuvy, Gablofen, Lioresal, Lyvispah, Ozobax) (PDF) |
CP.PHAR.149 |
January 1, 2025 |
Belantamab Mafodotin-blmf (Blenrep) (PDF) |
CP.PHAR.469 |
June 1, 2024 |
Belatacept (Nulojix) (PDF) |
CP.PHAR.201 |
Retire by January 1, 2025 |
Belatacept (Nulojix) (PDF) |
CP.PHAR.201 |
January 1, 2025 |
Belimumab (Benlysta) (PDF) |
CP.PHAR.88 |
October 1, 2024 |
Belinostat (Beleodaq) (PDF) |
CP.PHAR.311 |
Retire by March 1, 2025 |
Belinostat (Beleodaq) (PDF) |
CP.PHAR.311 |
March 1, 2025 |
Bendamustine (Belrapzo, Bendeka, Treanda, Vivimusta) (PDF) |
CP.PHAR.307 |
May 1, 2025 |
Bendamustine (Belrapzo, Bendeka, Treanda, Vivimusta) (PDF) |
CP.PHAR.307 |
March 1, 2025 |
Benralizumab (Fasenra) (PDF) |
HIM.PA.SP70 |
March 1, 2025 |
Beremagene geperpavec-svdt (Vyjuvek) (PDF) |
CP.PHAR.592 |
September 1, 2024 |
Betibeglogene Autotemcel (Zynteglo) (PDF) |
CP.PHAR.545 |
October 1, 2024 |
Bevacizumab (Alymsys, Avastin, Mvasi, Vegzelma, Zirabev) (PDF) |
CP.PHAR.93 |
Retire by March 1, 2025 |
Bevacizumab (Alymsys, Avastin, Mvasi, Vegzelma, Zirabev) (PDF) |
CP.PHAR.93 |
March 1, 2025 |
Bezlotoxumab (Zinplava) (PDF) |
CP.PHAR.300 |
May 1, 2024 |
Bimatoprost Implant (Durysta) (PDF) |
CP.PHAR.486 |
June 1, 2024 |
Biologic and Non-biologic DMARDs (PDF) |
HIM.PA.SP60 |
Retire by January 1, 2025 |
Biologic and Non-biologic DMARDs (PDF) |
HIM.PA.SP60 |
January 1, 2025 |
Blinatumomab (Blincyto) (PDF) |
CP.PHAR.312 |
November 1, 2024 |
Bortezomib (Velcade) (PDF) |
CP.PHAR.410 |
May 1, 2024 |
Brentuximab Vedotin (Adcetris) (PDF) |
CP.PHAR.303 |
October 1, 2024 |
Brexanolone (Zulresso) (PDF) |
CP.PHAR.417 |
June 1, 2024 |
Brexucabtagene Autoleucel (Tecartus) (PDF) |
CP.PHAR.472 |
May 1, 2024 |
Brivaracetam (Briviact) (PDF) |
CP.PMN.297 |
January 1, 2025 |
Brolucizumab-dbll (Beovu) (PDF) |
CP.PHAR.445 |
May 1, 2024 |
Buprenorphine Injection (Sublocade, Brixadi) (PDF) |
CP.PHAR.289 |
June 1, 2024 |
Burosumab-twza (Crysvita) (PDF) |
CP.PHAR.11 |
May 1, 2024 |
C1 Esterase Inhibitors (Berinert, Cinryze, Haegarda, Ruconest) (PDF) |
HIM.PA.170 |
September 1, 2024 |
Cabazitaxel (Jevtana) (PDF) |
CP.PHAR.316 |
June 1, 2024 |
Cabotegravir (Apretude), Cabotegravir/Rilpivirine (Cabenuva) (PDF) |
CP.PHAR.573 |
October 1, 2024 |
Canakinumab (Ilaris) (PDF) |
CP.PHAR.246 |
July 1, 2024 |
Caplacizumab-yhdp (Cablivi) (PDF) |
CP.PHAR.416 |
June 1, 2024 |
CarbidopaLevodopa (Crexont, Rytary,Duopa, Dhivy), FoscarbidopaLevodopa (Vyalev) (PDF) |
CP.PMN.238 |
January 1, 2025 |
Carfilzomib (Kyprolis) (PDF) |
CP.PHAR.309 |
Retire by March 1, 2025 |
Carfilzomib (Kyprolis) (PDF) |
CP.PHAR.309 |
March 1, 2025 |
Casimersen (Amondys 45) (PDF) |
CP.PHAR.470 |
May 1, 2024 |
Cemiplimab-rwlc (Libtayo) (PDF) |
CP.PHAR.397 |
Retire by January 1, 2025 |
Cemiplimab-rwlc (Libtayo) (PDF) |
CP.PHAR.397 |
January 1, 2025 |
Cerliponase alfa (Brineura) (PDF) |
CP.PHAR.338 |
October 1, 2024 |
Cetuximab (Erbitux) (PDF) |
CP.PHAR.317 |
Retire by March 1, 2025 |
Cetuximab (Erbitux) (PDF) |
CP.PHAR.317 |
March 1, 2025 |
Chloramphenicol Sodium Succinate (PDF) |
CP.PHAR.388 |
September 1, 2024 |
Ciltacabtagene Autoleucel (Carvykti) (PDF) |
CP.PHAR.533 |
Retire by January 1, 2025 |
Ciltacabtagene Autoleucel (Carvykti) (PDF) |
CP.PHAR.533 |
January 1, 2025 |
Collagenase Clostridium Histolyticum (Xiaflex) (PDF) |
CP.PHAR.82 |
September 1, 2024 |
Copanlisib (Aliqopa) (PDF) |
CP.PHAR.357 |
Retire by March 1, 2025 |
Copanlisib (Aliqopa) (PDF) |
CP.PHAR.357 |
March 1, 2025 |
Corticosteroids for Ophthalmic Injection (Dextenza, Iluvien, Ozurdex, Retisert, Xipere, Yutiq) (PDF) |
CP.PHAR.385 |
November 1, 2024 |
Cosyntropin (Cortrosyn) (PDF) |
CP.PHAR.203 |
May 1, 2024 |
Crizanlizumab-tmca (Adakveo) (PDF) |
CP.PHAR.449 |
May 1, 2024 |
Cytomegalovirus Immune Globulin (Cytogam) (PDF) |
CP.PHAR.277 |
September 1, 2024 |
Daprodustat (Jesduvroq) (PDF) |
CP.PHAR.628 |
August 1, 2024 |
Daptomycin (Cubicin, Cubicin RF, Dapzura RT) (PDF) |
CP.PHAR.351 |
September 1, 2024 |
Daratumumab (Darzalex), Daratumumab/Hyaluronidase-fihj (Darzalex Faspro) (PDF) |
CP.PHAR.310 |
November 1, 2024 |
Darolutamide (Nubeqa) (PDF) |
CP.PHAR.435 |
January 1, 2025 |
Daunorubicin/Cytarabine (Vyxeos) (PDF) |
CP.PHAR.352 |
Retire by January 1, 2025 |
Daunorubicin/Cytarabine (Vyxeos) (PDF) |
CP.PHAR.352 |
January 1, 2025 |
DaxibotulinumtoxinA-lanm (Daxxify) (PDF) |
CP.PHAR.651 |
Retire by January 1, 2025 |
DaxibotulinumtoxinA-lanm (Daxxify) (PDF) |
CP.PHAR.651 |
January 1, 2025 |
Deferoxamine (Desferal) (PDF) |
CP.PHAR.146 |
September 1, 2024 |
Degarelix Acetate (Firmagon) (PDF) |
CP.PHAR.170 |
Retire by January 1, 2025 |
Degarelix Acetate (Firmagon) (PDF) |
CP.PHAR.170 |
January 1, 2025 |
Delafloxacin (Baxdela) (PDF) |
CP.PMN.115 |
September 1, 2024 |
Delandistrogene Moxeparvovec-rokl (Elevidys) (PDF) |
CP.PHAR.593 |
November 1, 2024 |
Denileukin Diftitox-cxdl (Lymphir) (PDF) |
CP.PHAR.693 |
January 1, 2025 |
Denosumab (Prolia, Xgeva) (PDF) |
CP.PHAR.58 |
November 1, 2024 |
Dexrazoxane (Totect) (PDF) |
CP.PHAR.418 |
July 1, 2024 |
Donanemab-azbt (Kisunla) (PDF) |
CP.PHAR.594 |
March 1, 2025 |
Dostarlimab-gxly (Jemperli) (PDF) |
CP.PHAR.540 |
November 1, 2024 |
Durvalumab (Imfinzi) (PDF) |
CP.PHAR.339 |
November 1, 2024 |
Ecallantide (Kalbitor) (PDF) |
CP.PHAR.177 |
September 1, 2024 |
Eculizumab (Soliris), Eculizumab-aeeb (Bkemv), Eculizumab-aagh (Epysqli) (PDF) |
CP.PHAR.97 |
October 1, 2024 |
Edaravone (Radicava, Radicava ORS) (PDF) |
CP.PHAR.343 |
June 1, 2024 |
Efgartigimod Alfa-fcab, Efgartigimod/-Hyaluronidase-qvfc (Vyvgart, Vyvgart Hytrulo) (PDF) |
CP.PHAR.555 |
Retire by January 1, 2025 |
Efgartigimod Alfa-fcab, Efgartigimod/-Hyaluronidase-qvfc (Vyvgart, Vyvgart Hytrulo) (PDF) |
CP.PHAR.555 |
January 1, 2025 |
Elapegademase-lvlr (Revcovi) (PDF) |
CP.PHAR.419 |
June 1, 2024 |
Elivaldogene Autotemcel (Skysona) (PDF) |
CP.PHAR.556 |
Retire by January 1, 2025 |
Elivaldogene Autotemcel (Skysona) (PDF) |
CP.PHAR.556 |
January 1, 2025 |
Elosulfase Alfa (Vimizim) (PDF) |
CP.PHAR.162 |
June 1, 2024 |
Elotuzumab (Empliciti) (PDF) |
CP.PHAR.308 |
Retire by March 1, 2025 |
Elotuzumab (Empliciti) (PDF) |
CP.PHAR.308 |
March 1, 2025 |
Elranatamab-bcmm (Elrexfio) (PDF) |
CP.PHAR.652 |
Retire by January 1, 2025 |
Elranatamab-bcmm (Elrexfio) (PDF) |
CP.PHAR.652 |
January 1, 2025 |
Emapalumab-lzsg (Gamifant) (PDF) |
CP.PHAR.402 |
May 1, 2024 |
Enfortumab Vedotin-ejfv (Padcev) (PDF) |
CP.PHAR.455 |
May 1, 2024 |
Enfuvirtide (Fuzeon) (PDF) |
CP.PHAR.41 |
August 1, 2024 |
Entyvio |
QCP.PHAR.002 |
Retire by January 1, 2025 |
Epcoritamab-bysp (Epkinly) (PDF) |
CP.PHAR.634 |
September 1, 2024 |
Epoetin Alfa (Epogen, Procrit), Epoetin Alfa-epbx (Retacrit) (PDF) |
CP.PHAR.237 |
August 1, 2024 |
Epoprostenol (Flolan, Veletri) (PDF) |
CP.PHAR.192 |
May 1, 2024 |
Eptinezumab-jjmr (Vyepti) (PDF) |
HIM.PA.SP64 |
Retire by March 1, 2025 |
Eptinezumab-jjmr (Vyepti) (PDF) |
HIM.PA.SP64 |
March 1, 2025 |
Eribulin Mesylate (Halaven) (PDF) |
CP.PHAR.318 |
Retire by January 1, 2025 |
Eribulin Mesylate (Halaven) (PDF) |
CP.PHAR.318 |
January 1, 2025 |
Erwinia Asparaginase (Erwinaze, Rylaze) (PDF) |
CP.PHAR.301 |
May 1, 2024 |
Esketamine (Spravato) (PDF) |
CP.PMN.199 |
May 1, 2024 |
Etelcalcetide (Parsabiv) (PDF) |
CP.PHAR.379 |
September 1, 2024 |
Eteplirsen (Exondys 51) (PDF) |
CP.PHAR.288 |
May 1, 2024 |
Etranacogene Dezaparvovec-drlb (Hemgenix) (PDF) |
CP.PHAR.580 |
Retire by March 1, 2025 |
Etranacogene Dezaparvovec-drlb (Hemgenix) (PDF) |
CP.PHAR.580 |
March 1, 2025 |
Evinacumab-dgnb (Evkeeza) (PDF) |
HIM.PA.166 |
May 1, 2024 |
Exagamglogene autotemcel (Casgevy) (PDF) |
CP.PHAR.603 |
July 1, 2024 |
Factor IX (Human, Recombinant) (PDF) |
CP.PHAR.218 |
June 1, 2024 |
Factor IX Complex, Human (Profilnine) (PDF) |
CP.PHAR.219 |
June 1, 2024 |
Factor VIIa, Recombinant (NovoSeven RT, SevenFact) (PDF) |
CP.PHAR.220 |
September 1, 2024 |
Factor VIII (Human, Recombinant) (PDF) |
CP.PHAR.215 |
June 1, 2024 |
Factor VIII/von Willebrand Factor Complex (Human – Alphanate, Humate-P, Wilate); von Willebrand Factor (Recombinant – Vonvendi) (PDF) |
CP.PHAR.216 |
June 1, 2024 |
Factor XIII A-Subunit, Recombinant (Tretten) (PDF) |
CP.PHAR.222 |
May 1, 2024 |
Factor XIII, Human (Corifact) (PDF) |
CP.PHAR.221 |
May 1, 2024 |
Fam-Trastuzumab Deruxtecan-nxki (Enhertu) (PDF) |
CP.PHAR.456 |
August 1, 2024 |
Faricimab-svoa (Vabysmo) (PDF) |
CP.PHAR.581 |
October 1, 2024 |
Ferric Carboxymaltose (Injectafer) (PDF) |
CP.PHAR.234 |
September 1, 2024 |
Ferric Derisomaltose (Monoferric) (PDF) |
CP.PHAR.480 |
November 1, 2024 |
Ferric Pyrophosphate (Triferic, Triferic Avnu ) (PDF) |
CP.PHAR.624 |
June 1, 2024 |
Ferumoxytol (Feraheme) (PDF) |
CP.PHAR.165 |
September 1, 2024 |
Fibrinogen Concentrate [Human] (Fibryga, RiaSTAP) (PDF) |
CP.PHAR.526 |
November 1, 2024 |
Fidanacogene Elaparvovec-dzkt (Beqvez) (PDF) |
CP.PHAR.643 |
Retire by January 1, 2025 |
Fidanacogene Elaparvovec-dzkt (Beqvez) (PDF) |
CP.PHAR.643 |
January 1, 2025 |
Filgrastim (Neupogen, Zarxio, Granix, Nivestym, Releuko, Nypozi) (PDF) |
CP.PHAR.297 |
January 1, 2025 |
Fosdenopterin (Nulibry) (PDF) |
CP.PHAR.471 |
June 1, 2024 |
Fulvestrant (Faslodex Injection) (PDF) |
CP.PHAR.424 |
October 1, 2024 |
Galsulfase (Naglazyme) (PDF) |
CP.PHAR.161 |
June 1, 2024 |
Gemtuzumab Ozogamicin (Mylotarg) (PDF) |
CP.PHAR.358 |
Retire by January 1, 2025 |
Gemtuzumab Ozogamicin (Mylotarg) (PDF) |
CP.PHAR.358 |
January 1, 2025 |
Givosiran (Givlaari) (PDF) |
CP.PHAR.457 |
May 1, 2024 |
Glofitamab-gxbm (Columvi) (PDF) |
CP.PHAR.636 |
September 1, 2024 |
Golodirsen (Vyondys 53) (PDF) |
CP.PHAR.453 |
May 1, 2024 |
Goserelin Acetate (Zoladex) (PDF) |
CP.PHAR.171 |
Retire by January 1, 2025 |
Goserelin Acetate (Zoladex) (PDF) |
CP.PHAR.171 |
January 1, 2025 |
Granisetron (Sancuso, Sustol) (PDF) |
CP.PMN.74 |
January 1, 2025 |
Hemin (Panhematin) (PDF) |
CP.PHAR.181 |
May 1, 2024 |
Histrelin Acetate (Vantas, Supprelin LA) (PDF) |
CP.PHAR.172 |
July 1, 2024 |
Ibalizumab-uiyk (Trogarzo) (PDF) |
CP.PHAR.378 |
August 1, 2024 |
Ibandronate Injection (Boniva) (PDF) |
CP.PHAR.189 |
May 1, 2024 |
Idecabtagene Vicleucel (Abecma) (PDF) |
CP.PHAR.481 |
Retire by January 1, 2025 |
Idecabtagene Vicleucel (Abecma) (PDF) |
CP.PHAR.481 |
January 1, 2025 |
Idursulfase (Elaprase) (PDF) |
CP.PHAR.156 |
June 1, 2024 |
Iloperidone (Fanapt) (PDF) |
CP.PMN.32 |
January 1, 2025 |
Imetelstat (Rytelo) (PDF) |
CP.PHAR.690 |
September 1, 2024 |
Imiglucerase (Cerezyme) (PDF) |
CP.PHAR.154 |
June 1, 2024 |
Immune Globulins (PDF) |
CP.PHAR.103 |
Retire by January 1, 2025 |
Immune Globulins (PDF) |
CP.PHAR.103 |
January 1, 2025 |
Inclisiran (Leqvio) (PDF) |
CP.PHAR.568 |
May 1, 2024 |
IncobotulinumtoxinA (Xeomin) (PDF) |
CP.PHAR.231 |
October 1, 2024 |
Inebilizumab-cdon (Uplizna) (PDF) |
CP.PHAR.458 |
October 1, 2024 |
Infliximab |
QCP.PHAR.003 |
Retire by January 1, 2025 |
Inotuzumab Ozogamicin (Besponsa) (PDF) |
CP.PHAR.359 |
Retire by January 1, 2025 |
Inotuzumab Ozogamicin (Besponsa) (PDF) |
CP.PHAR.359 |
January 1, 2025 |
Insulin Delivery Systems (V-Go, Omnipod, InPen) (PDF) |
CP.PHAR.534 |
November 1, 2024 |
Interferon Gamma- 1b (Actimmune) (PDF) |
CP.PHAR.52 |
May 1, 2024 |
Iobenguane I-131 (Azedra) (PDF) |
CP.PHAR.459 |
May 1, 2024 |
Ipilimumab (Yervoy) (PDF) |
CP.PHAR.319 |
June 1, 2024 |
Irinotecan Liposome (Onivyde) (PDF) |
CP.PHAR.304 |
Retire by January 1, 2025 |
Irinotecan Liposome (Onivyde) (PDF) |
CP.PHAR.304 |
January 1, 2025 |
Isatuximab-irfc (Sarclisa) (PDF) |
CP.PHAR.482 |
June 1, 2024 |
Isavuconazonium (Cresemba) (PDF) |
CP.PMN.154 |
June 1, 2024 |
Isotretinoin (Claravis Absorica Absorica LD Myorisan Zenatane Amnesteem) (PDF) |
CP.PMN.143 |
March 1, 2025 |
Ketamine (Ketalar) (PDF) |
CP.PMN.296 |
September 1, 2024 |
Lanadelumab-fylo (Takhzyro) (PDF) |
HIM.PA.172 |
May 1, 2024 |
Lanreotide (Somatuline Depot and Unbranded) (PDF) |
CP.PHAR.391 |
Retire by January 1, 2025 |
Lanreotide (Somatuline Depot and Unbranded) (PDF) |
CP.PHAR.391 |
January 1, 2025 |
Laronidase (Aldurazyme) (PDF) |
CP.PHAR.152 |
June 1, 2024 |
Lazertinib (Lazcluze) (PDF) |
CP.PHAR.695 |
January 1, 2025 |
Lecanemab-irmb (Leqembi) (PDF) |
CP.PHAR.596 |
Retire by March 1, 2025 |
Lecanemab-irmb (Leqembi) (PDF) |
CP.PHAR.596 |
March 1, 2025 |
Lefamulin (Xenleta) (PDF) |
CP.PMN.219 |
September 1, 2024 |
Lenacapavir (Sunlenca) (PDF) |
CP.PHAR.622 |
May 1, 2024 |
Letermovir (Prevymis) (PDF) |
CP.PHAR.367 |
January 1, 2025 |
Letermovir (Prevymis) (PDF) |
CP.PHAR.367 |
Retire by January 1, 2025 |
Leucovorin Injection (PDF) |
CP.PHAR.393 |
May 1, 2024 |
Leuprolide Acetate (Lupron, Eligard, Lupaneta Pack, Fensolvi, Camcevi) (PDF) |
CP.PCH.53 |
January 1, 2025 |
Leuprolide Acetate (Eligard, Fensolvi, Lupaneta Pack, Lupron Depot, Lupron Depot-Ped), Leuprolide mesylate (Camcevi) (PDF) |
CP.PHAR.173 |
May 1, 2024 |
Levoleucovorin (Fusilev, Khapzory) (PDF) |
CP.PHAR.151 |
Retire by January 1, 2025 |
Levoleucovorin (Fusilev, Khapzory) (PDF) |
CP.PHAR.151 |
January 1, 2025 |
Lifileucel (Amtagvi) (PDF) |
CP.PHAR.598 |
January 1, 2025 |
Linezolid (Zyvox) (PDF) |
CP.PMN.27 |
August 1, 2024 |
Lisocabtagene Maraleucel (Breyanzi) (PDF) |
CP.PHAR.483 |
August 1, 2024 |
Loncastuximab Tesirine-lpyl (Zynlonta) (PDF) |
CP.PHAR.539 |
September 1, 2024 |
Lovotibeglogene Autotemcel (Lyfgenia) (PDF) |
CP.PHAR.627 |
August 1, 2024 |
Lumasiran (Oxlumo) (PDF) |
CP.PHAR.473 |
August 1, 2024 |
Lurbinectedin (Zepzelca) (PDF) |
CP.PHAR.500 |
September 1, 2024 |
Luspatercept-aamt (Reblozyl) (PDF) |
CP.PHAR.450 |
December 1, 2024 |
Lutetium Lu 177 dotatate (Lutathera) (PDF) |
CP.PHAR.384 |
September 1, 2024 |
Lutetium Lu 177 vipivotide tetraxetan (Pluvicto) (PDF) |
CP.PHAR.582 |
June 1, 2024 |
Margetuximab-cmkb (Margenza) (PDF) |
CP.PHAR.522 |
May 1, 2024 |
Mecasermin (Increlex) (PDF) |
CP.PHAR.150 |
October 1, 2024 |
Melphalan (Hepzato) (PDF) |
CP.PHAR.653 |
Retire by January 1, 2025 |
Melphalan (Hepzato) (PDF) |
CP.PHAR.653 |
January 1, 2025 |
Melphalan flufenamide (Pepaxto) (PDF) |
CP.PHAR.535 |
June 1, 2024 |
Mepolizumab (Nucala) (PDF) |
CP.PHAR.200 |
January 1, 2025 |
Methoxsalen (Uvadex) (PDF) |
HIM.PA.17 |
Retire by January 1, 2025 |
Methoxsalen (Uvadex) (PDF) |
HIM.PA.17 |
January 1, 2025 |
Metreleptin (Myalept) (PDF) |
CP.PHAR.425 |
September 1, 2024 |
Mirvetuximab soravatansine-gynx (Elahere) (PDF) |
CP.PHAR.617 |
July 1, 2024 |
Mitomycin for Pyelocalyceal Solution (Jelmyto) (PDF) |
CP.PHAR.495 |
September 1, 2024 |
Mitoxantrone (PDF) |
CP.PHAR.258 |
July 1, 2024 |
Mogamulizumab-kpkc (Poteligeo) (PDF) |
CP.PHAR.139 |
Retire by March 1, 2025 |
Mogamulizumab-kpkc (Poteligeo) (PDF) |
CP.PHAR.139 |
March 1, 2025 |
Mometasone Furoate (Sinuva) (PDF) |
CP.PHAR.448 |
August 1, 2024 |
Mosunetuzumab-axgb (Lunsumio) (PDF) |
CP.PHAR.618 |
May 1, 2024 |
Motixafortide (Aphexda) (PDF) |
CP.PHAR.655 |
Retire by January 1, 2025 |
Motixafortide (Aphexda) (PDF) |
CP.PHAR.655 |
January 1, 2025 |
Moxetumomab pasudotox-tdfk (Lumoxiti) (PDF) |
CP.PHAR.398 |
Retire by January 1, 2025 |
Moxetumomab pasudotox-tdfk (Lumoxiti) (PDF) |
CP.PHAR.398 |
January 1, 2025 |
Nadofaragene Firadenovec-vncg (Adstiladrin) (PDF) |
CP.PHAR.461 |
Retire by March 1, 2025 |
Nadofaragene Firadenovec-vncg (Adstiladrin) (PDF) |
CP.PHAR.461 |
March 1, 2025 |
Natalizumab (Tysabri) (PDF) |
CP.PHAR.259 |
September 1, 2024 |
Naxitamab-gqgk (Danyelza) (PDF) |
CP.PHAR.523 |
May 1, 2024 |
Necitumumab (Portrazza) (PDF) |
CP.PHAR.320 |
Retire by January 1, 2025 |
Necitumumab (Portrazza) (PDF) |
CP.PHAR.320 |
January 1, 2025 |
Nedosiran (Rivfloza) (PDF) |
CP.PHAR.619 |
August 1, 2024 |
Nemolizumab-ito (Nemluvio) (PDF) |
CP.PHAR.703 |
January 1, 2025 |
Nirsevimab-alip (Beyfortus) (PDF) |
CP.PHAR.614 |
September 1, 2024 |
Nivolumab (Opdivo) (PDF) |
CP.PHAR.121 |
Retire by March 1, 2025 |
Nivolumab (Opdivo) (PDF) |
CP.PHAR.121 |
March 1, 2025 |
Nivolumab and Relatlimab-rmbw (Opdualag) (PDF) |
CP.PHAR.588 |
September 1, 2024 |
No Coverage Criteria, Recent Label Changes Pending Clinical Policy Update (PDF) |
HIM.PA.33 |
January 1, 2024 |
Nogapendekin alfa inbakicept-pmln (Anktiva) (PDF) |
CP.PHAR.684 |
September 1, 2024 |
Nusinersen (Spinraza) (PDF) |
CP.PHAR.327 |
May 1, 2024 |
Obinutuzumab (Gazyva) (PDF) |
CP.PHAR.305 |
Retire by January 1, 2025 |
Obinutuzumab (Gazyva) (PDF) |
CP.PHAR.305 |
January 1, 2025 |
Off-Label Drug Use (PDF) |
HIM.PA.154 |
January 1, 2025 |
Ocrelizumab (Ocrevus) (PDF) |
CP.PHAR.335 |
June 1, 2024 |
Octreotide Acetate (Sandostatin, Sandostatin LAR Depot, Bynfezia, Mycapssa) (PDF) |
CP.PHAR.40 |
September 1, 2024 |
Ofatumumab (Arzerra, Kesimpta) (PDF) |
CP.PHAR.306 |
June 1, 2024 |
Olanzapine Long-Acting Injection (Zyprexa Relprevv) (PDF) |
CP.PHAR.292 |
May 1, 2024 |
Olipudase Alfa-rpcp (Xenpozyme) (PDF) |
CP.PHAR.586 |
September 1, 2024 |
Omacetaxine (Synribo) (PDF) |
CP.PHAR.108 |
June 1, 2024 |
Omadacycline (Nuzyra) (PDF) |
CP.PMN.188 |
September 1, 2024 |
OnabotulinumtoxinA (Botox) (PDF) |
CP.PHAR.232 |
Retire by January 1, 2025 |
OnabotulinumtoxinA (Botox) (PDF) |
CP.PHAR.232 |
January 1, 2025 |
Onasemnogene Abeparvovec (Zolgensma) (PDF) |
CP.PHAR.421 |
September 1, 2024 |
Orencia (PDF) |
QCP.PHAR.004 |
Retire by January 1, 2025 |
Paclitaxel, Protein-Bound (Abraxane) (PDF) |
CP.PHAR.176 |
November 1, 2024 |
Paliperidone Long-Acting Injections (Invega Hafyera, Invega Sustenna, Invega Trinza) (PDF) |
CP.PHAR.291 |
May 1, 2024 |
Palivizumab (Synagis) (PDF) |
CP.PHAR.16 |
May 1, 2024 |
Panitumumab (Vectibix) (PDF) |
CP.PHAR.321 |
Retire by March 1, 2025 |
Panitumumab (Vectibix) (PDF) |
CP.PHAR.321 |
March 1, 2025 |
Paricalcitol Injection (Zemplar) (PDF) |
CP.PHAR.270 |
September 1, 2024 |
Pasireotide (Signifor, Signifor LAR) (PDF) |
CP.PHAR.332 |
Retire by January 1, 2025 |
Pasireotide (Signifor, Signifor LAR) (PDF) |
CP.PHAR.332 |
January 1, 2025 |
Patisiran (Onpattro) (PDF) |
CP.PHAR.395 |
July 1, 2024 |
Pegaspargase (Oncaspar), Calaspargase Pegol-mknl (Asparlas) (PDF) |
CP.PHAR.353 |
Retire by March 1, 2025 |
Pegaspargase (Oncaspar), Calaspargase Pegol-mknl (Asparlas) (PDF) |
CP.PHAR.353 |
March 1, 2025 |
Pegcetacoplan (Empaveli, APL-2) (PDF) |
CP.PHAR.524 |
October 1, 2024 |
Pegloticase (Krystexxa) (PDF) |
CP.PHAR.115 |
May 1, 2024 |
Pegunigalsidase Alfa-iwxj (Elfabrio) (PDF) |
CP.PHAR.512 |
September 1, 2024 |
Pegvaliase-pqpz (Palynziq) (PDF) |
CP.PHAR.140 |
Retire by March 1, 2025 |
Pegvaliase-pqpz (Palynziq) (PDF) |
CP.PHAR.140 |
March 1, 2025 |
Pegvisomant (Somavert) (PDF) |
CP.PHAR.389 |
Retire by January 1, 2025 |
Pegvisomant (Somavert) (PDF) |
CP.PHAR.389 |
January 1, 2025 |
Pembrolizumab (Keytruda) (PDF) |
CP.PHAR.322 |
Retire by January 1, 2025 |
Pembrolizumab (Keytruda) (PDF) |
CP.PHAR.322 |
January 1, 2025 |
Pemetrexed (Alimta, Pemfexy) (PDF) |
CP.PHAR.368 |
May 1, 2024 |
Pertuzumab (Perjeta) (PDF) |
CP.PHAR.227 |
June 1, 2024 |
Pertuzumab/Trastuzumab/Hyaluronidase-zzxf (Phesgo) (PDF) |
CP.PHAR.501 |
September 1, 2024 |
Plasminogen, human-tvmh (Ryplazim) (PDF) |
CP.PHAR.513 |
Retire by January 1, 2025 |
Plasminogen, human-tvmh (Ryplazim) (PDF) |
CP.PHAR.513 |
January 1, 2025 |
Plerixafor (Mozobil) (PDF) |
CP.PHAR.323 |
October 1, 2024 |
Polatuzumab Vedotin-piiq (Polivy) (PDF) |
CP.PHAR.433 |
September 1, 2024 |
Pozelimab-bbfg (Veopoz) (PDF) |
CP.PHAR.626 |
June 1, 2024 |
Pralatrexate (Folotyn) (PDF) |
CP.PHAR.313 |
Retire by March 1, 2025 |
Pralatrexate (Folotyn) (PDF) |
CP.PHAR.313 |
March 1, 2025 |
Protein C Concentrate, Human (Ceprotin) (PDF) |
CP.PHAR.330 |
May 1, 2024 |
Ramucirumab (Cyramza) (PDF) |
CP.PHAR.119 |
May 1, 2024 |
Ranibizumab (Byooviz, Cimerli, Lucentis, Susvimo) (PDF) |
CP.PHAR.186 |
January 1, 2025 |
Ranibizumab (Byooviz, Cimerli, Lucentis, Susvimo) (PDF) |
CP.PHAR.186 |
Retire by January 1, 2025 |
Ravulizumab-cwvz (Ultomiris) (PDF) |
CP.PHAR.415 |
October 1, 2024 |
Reslizumab (Cinqair) (PDF) |
CP.PHAR.223 |
May 1, 2024 |
Repository Corticotropin Injection (H.P. Acthar Gel, Purified Cortrophin Gel) (PDF) |
HIM.PA.168 |
May 1, 2024 |
Respiratory syncytial virus vaccine (Abrysvo) (PDF) |
CP.PHAR.658 |
Retire by January 1, 2025 |
Respiratory syncytial virus vaccine (Abrysvo) (PDF) |
CP.PHAR.658 |
January 1, 2025 |
Retifanlimab-dlwr (Zynyz) (PDF) |
CP.PHAR.629 |
July 1, 2024 |
Ribociclib (Kisqali, Kisqali Femara) (PDF) |
CP.PHAR.334 |
March 1, 2025 |
Rilonacept (Arcalyst) (PDF) |
CP.PHAR.266 |
July 1, 2024 |
RimabotulinumtoxinB (Myobloc) (PDF) |
CP.PHAR.233 |
June 1, 2024 |
Risdiplam (Evrysdi) (PDF) |
CP.PHAR.477 |
May 1, 2024 |
Risperidone Long-Acting Injection (Perseris, Risperdal Consta, Rykindo, Uzedy) (PDF) |
CP.PHAR.293 |
May 1, 2024 |
Rituximab (Rituxan), Rituximab-arrx (Riabni), Rituximab-pvvr (Ruxience), Rituximab-abbs (Truxima), Rituximab-Hyaluronidase (Rituxan Hycela) (PDF) |
CP.PHAR.260 |
August 1, 2024 |
Romidepsin (Istodax) (PDF) |
CP.PHAR.314 |
Retire by January 1, 2025 |
Romidepsin (Istodax) (PDF) |
CP.PHAR.314 |
January 1, 2025 |
Romiplostim (Nplate) (PDF) |
CP.PHAR.179 |
May 1, 2024 |
Romosozumab-aqqg (Evenity) (PDF) |
CP.PHAR.428 |
January 1, 2025 |
Ropeginterferon Alfa-2b-njft (BESREMi) (PDF) |
CP.PHAR.570 |
July 1, 2024 |
Rozanolixizumab-noli (Rystiggo) (PDF) |
CP.PHAR.648 |
Retire by March 1, 2025 |
Rozanolixizumab-noli (Rystiggo) (PDF) |
CP.PHAR.648 |
March 1, 2025 |
Sacituzumab Govitecan-hziy (Trodelvy) (PDF) |
CP.PHAR.475 |
June 1, 2024 |
Sargramostim (Leukine) (PDF) |
CP.PHAR.295 |
October 1, 2024 |
Satralizumab-mwge (Enspryng) (PDF) |
CP.PHAR.463 |
October 1, 2024 |
Sebelipase Alfa (Kanuma) (PDF) |
CP.PHAR.159 |
June 1, 2024 |
Secukinumab (Cosentyx) (PDF) |
QCP.PHAR.008 |
Retire by January 1, 2025 |
Selpercatinib (Retevmo) (PDF) |
CP.PHAR.478 |
January 1, 2025 |
Sepsis Diagnosis (PDF) |
CC.PP.073 |
November 1, 2024 |
Siltuximab (Sylvant) (PDF) |
CP.PHAR.329 |
May 1, 2024 |
Simponi Aria |
QCP.PHAR.005 |
Retire by January 1, 2025 |
Sirolimus Protein-Bound Particles (Fyarro), Topical Gel (Hyftor) (PDF) |
CP.PHAR.574 |
May 1, 2024 |
Skyrizi |
QCP.PHAR.006 |
Retire by January 1, 2025 |
Sodium Oxybate (Xyrem, Lumryz) and Calcium Magnesium Potassium Sodium Oxybate (Xywav) (PDF) |
CP.PMN.42 |
January 1, 2025 |
Sodium thiosulfate (Pedmark) (PDF) |
CP.PHAR.610 |
June 1, 2024 |
Sparsentan (Filspari) (PDF) |
CP.PHAR.631 |
January 1, 2025 |
Spesolimab-sbzo (Spevigo) (PDF) |
CP.PHAR.606 |
August 1, 2024 |
Stelara |
QCP.PHAR.007 |
Retire by January 1, 2025 |
Sutimlimab-jome (Enjaymo) (PDF) |
CP.PHAR.503 |
June 1, 2024 |
Tafasitamab-cxix (Monjuvi) (PDF) |
CP.PHAR.508 |
Retire by March 1, 2024 |
Tafasitamab-cxix (Monjuvi) (PDF) |
CP.PHAR.508 |
March 1, 2024 |
Taliglucerase Alfa (Elelyso) (PDF) |
CP.PHAR.157 |
June 1, 2024 |
Talimogene laherepvec (Imlygic) (PDF) |
CP.PHAR.542 |
September 1, 2024 |
Talquetamab-tgvs (Talvey) (PDF) |
CP.PHAR.649 |
Retire by March 1, 2025 |
Talquetamab-tgvs (Talvey) (PDF) |
CP.PHAR.649 |
March 1, 2025 |
Tarlatamab-dlle (Imdelltra) (PDF) |
CP.PHAR.685 |
September 1, 2024 |
Tebentafusp-tebn (Kimmtrak) (PDF) |
CP.PHAR.575 |
June 1, 2024 |
Teclistamab-cqyv (Tecvayli) (PDF) |
CP.PHAR.611 |
May 1, 2024 |
Tedizolid (Sivextro) (PDF) |
CP.PMN.62 |
September 1, 2024 |
Temozolomide (Temodar) (PDF) |
CP.PHAR.77 |
May 1, 2024 |
Temsirolimus (Torisel) (PDF) |
CP.PHAR.324 |
Retire by January 1, 2025 |
Temsirolimus (Torisel) (PDF) |
CP.PHAR.324 |
January 1, 2025 |
Teplizumab-mzwv (Tzield) (PDF) |
CP.PHAR.492 |
May 1, 2024 |
Teprotumumab (Tepezza) (PDF) |
CP.PHAR.465 |
May 1, 2024 |
Testosterone (Testopel, Jatenzo, Kyzatrex, Tlando) (PDF) |
CP.PHAR.354 |
Retire by January 1, 2025 |
Testosterone (Testopel, Jatenzo, Kyzatrex, Tlando) (PDF) |
CP.PHAR.354 |
January 1, 2025 |
Tezepelumab-ekko (Tezspire) (PDF) |
CP.PHAR.576 |
May 1, 2024 |
Thyrotropin alfa (Thyrogen) (PDF) |
CP.PHAR.95 |
September 1, 2024 |
Tildrakizumab (Ilumya) |
QCP.PHAR.009 |
Retire by January 1, 2025 |
Tisagenlecleucel (Kymriah) (PDF) |
CP.PHAR.361 |
May 1, 2024 |
Tislelizumab-jsgr (Tevimbra) (PDF) |
CP.PHAR.687 |
November 1, 2024 |
Tisotumab Vedotin-tftv (Tivdak) (PDF) |
CP.PHAR.561 |
Retire by March 1, 2025 |
Tisotumab Vedotin-tftv (Tivdak) (PDF) |
CP.PHAR.561 |
March 1, 2025 |
Tofersen (Qalsody) (PDF) |
CP.PHAR.591 |
Retire by January 1, 2025 |
Tofersen (Qalsody) (PDF) |
CP.PHAR.591 |
January 1, 2025 |
Topotecan (Hycamtin) (PDF) |
CP.PHAR.64 |
July 1, 2024 |
Toripalimab (Loqtorzi) (PDF) |
CP.PHAR.668 |
September 1, 2024 |
Trabectedin (Yondelis) (PDF) |
CP.PHAR.204 |
May 1, 2024 |
Trastuzumab/Biosimilars, Trastuzumab-Hyaluronidase (PDF) |
CP.PHAR.228 |
August 1, 2024 |
Travoprost (iDose TR) (PDF) |
CP.PHAR.672 |
August 1, 2024 |
Tremelimumab-actl (Imjudo) (PDF) |
CP.PHAR.612 |
December 1, 2024 |
Triptorelin Pamoate (Trelstar, Triptodur) (PDF) |
CP.PHAR.175 |
Retire by January 1, 2025 |
Triptorelin Pamoate (Trelstar, Triptodur) (PDF) |
CP.PHAR.175 |
January 1, 2025 |
Ublituximab-xiiy (Briumvi) (PDF) |
CP.PHAR.621 |
June 1, 2024 |
Valoctocogene Roxaparvovec-rvox (Roctavian) (PDF) |
CP.PHAR.466 |
May 1, 2024 |
Valrubicin (Valstar) (PDF) |
CP.PHAR.439 |
Retire by March 1, 2025 |
Valrubicin (Valstar) (PDF) |
CP.PHAR.439 |
March 1, 2025 |
Velaglucerase Alfa (VPRIV) (PDF) |
CP.PHAR.163 |
June 1, 2024 |
Velmanase Alfa-tycv (Lamzede) (PDF) |
CP.PHAR.601 |
June 1, 2024 |
Velpatasvir (Epclusa) (PDF) |
HIM.PA.SP1 |
January 1, 2025 |
Verteporfin (Visudyne) (PDF) |
CP.PHAR.187 |
May 1, 2024 |
Vestronidase Alfa-vjbk (Mepsevii) (PDF) |
CP.PHAR.374 |
July 1, 2024 |
Viltolarsen (Viltepso) (PDF) |
CP.PHAR.484 |
May 1, 2024 |
Voretigene Neparvovec-rzyl (Luxturna) (PDF) |
CP.PHAR.372 |
May 1, 2024 |
Voxelotor (Oxbryta) (PDF) |
CP.PHAR.451 |
January 1, 2025 |
Zavegepant (Zavzpret) (PDF) |
CP.PHAR.630 |
Retire by March 1, 2025 |
Zavegepant (Zavzpret) (PDF) |
CP.PHAR.630 |
March 1, 2025 |
Ziv-aflibercept (Zaltrap) (PDF) |
CP.PHAR.325 |
Retire by January 1, 2025 |
Ziv-aflibercept (Zaltrap) (PDF) |
CP.PHAR.325 |
January 1, 2025 |
Zoledronic Acid (Reclast) (PDF) |
CP.PHAR.59 |
May 1, 2024 |